~~<i id='7F796645AE'><strike id='7F796645AE'><tt id='7F796645AE'><pre id='7F796645AE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

comprehensive

author：entertainment 2025-09-30 08:53:27 - browse：2974

Calling Bullshit course University of Washington — Screenshot via callingbullshit.org

Tired of alternative facts, fake news, and breathless hyperbole, two professors at the University of Washington are trying to strike a blow for science.

Their weapon? A new course: “Calling Bullshit In the Age of Big Data.”

The class website and colorful syllabus went online last month and almost instantly went viral.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Medicare’s new pay boost for primary care is angering specialists

focus

entertainment

leisure time

focus

explore

Wikipedia

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

WSS

Prior authorization will have to move faster under new Biden rule

Study suggests Covid rebound is far more common with Paxlovid than without

New brain studies show LSD's effects on the brain in full color

Ventyx halts psoriasis drug development after lackluster trial results

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

EU regulator recommends expanding Mounjaro approval to obesity

knowledge

comprehensive

focus

As demand for Covid shots wanes, Moderna seeks its next success

How state and local governments are sidelining science

Sports medicine is finally prioritizing gender equality

After decades in use, heart stents finally beat placebo

Dobbs anniversary: the lost opportunity of abortion as health care

Today's health inequities arise from racist U.S. history, say experts

23andMe had bad news about my health. I wish a person had delivered it

How digital therapeutics firms are pivoting after Pear's bankruptcy

Jerome Adams on the need for new antivirals for Covid

Ventyx halts psoriasis drug development after lackluster trial results

entertainment

Cancer diagnosis changes perspective doctor, former hospital CEO

Readout Newsletter: Zepbound, Valneva's vaccine, and more

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Study suggests Covid rebound is far more common with Paxlovid than without

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

What is STAT's opinion section for?

leisure time

focus

explore

Wikipedia